

Chief Executive Officer Remuneration Update

Genetic Signatures Limited [ASX:GSS] (“GSS” or “Company”), advises that in accordance with ASX Listing Rule 3.16.4 it has updated the remuneration arrangements for its Chief Executive Officer, Allison Rossiter.

Key changes

- **Base remuneration:** A\$515,000 per annum (exclusive of superannuation), effective from 1 October 2025.
- **Long-term incentive:** Performance Rights with a maximum value equivalent to 25% of base remuneration vesting in three years, subject to the achievement of long-term service and performance hurdles.

These changes follow a review by the Board. All other remuneration and termination arrangements, as announced on 4 June 2024, remain unchanged.

– END –

Announcement authorised for release by the Board of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter
Chief Executive Officer
allison.rossiter@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial Officer
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.